Related Experiment Videos
[Antiandrogen withdrawal syndrome]
1Department of Urology, Inoue Memorial Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|September 29, 1998
Summary
Antiandrogen withdrawal syndrome in prostate cancer patients involves stopping antiandrogen therapy, leading to decreased prostate-specific antigen and clinical improvement. Androgen receptor gene mutations are implicated in this response.
Area of Science:
- Oncology
- Endocrinology
- Molecular Biology
Context:
- Prostate cancer treatment often involves androgen deprivation therapy.
- Disease progression despite androgen blockage can occur.
- Antiandrogen withdrawal syndrome (AAWS) is a recognized phenomenon.
Purpose:
- To summarize the phenomenon of antiandrogen withdrawal syndrome in prostate cancer.
- To explore potential mechanisms, including androgen receptor (AR) gene mutations.
Summary:
- AAWS is observed in prostate cancer patients progressing on antiandrogens, where drug cessation leads to PSA decline and clinical response.
- This syndrome has been reported with various antiandrogens including flutamide and casodex.
- Mutations in the AR gene, similar to those in the LNCaP cell line, have been identified in patients with AAWS, suggesting a molecular basis.
Impact:
- Understanding AAWS can inform treatment strategies for advanced prostate cancer.
- Identification of AR mutations provides insights into treatment resistance.
- Further research into AR mutations may reveal new therapeutic targets.